Mizuho raised the firm’s price target on Encompass Health (EHC) to $130 from $110 and keeps an Outperform rating on the shares. The company reported strong Q1 results with adjusted EBITDA beating consensus, in part driven by strong volume, solid expense management and a favorable payer mix, the analyst tells investors in a research note. The firm believes Encompass Health’s earnings visibility is high and there is likely more upside to estimates going forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health: Strong Performance and Strategic Expansion Drive Buy Rating
- Encompass Health’s Strong Q1 2025 Performance and Strategic Moves Justify Buy Rating
- Encompass Health Stock (EHC) Surges Following Strong Q1 Results and Strategic Expansion Plans
- Encompass Health Reports Strong Q1 2025 Results
- Encompass Health rises 8.8%